My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
Intermedix
SIBFL
>
City Clerk
>
Bids-RFQ-RFP
>
RFP
>
RFP No. 11-12-01 Fleet Wide Remote Mgmt. System
>
Responses
>
Intermedix
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
6/18/2012 10:31:53 PM
Creation date
1/10/2012 1:43:48 PM
Metadata
Fields
Template:
CityClerk-Bids_RFP_RFQ
Project Name
Intermedix
Bid No. (xx-xx-xx)
11-12-01
Project Type (Bid, RFP, RFQ)
RFP
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
104
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
INTERMEDIX HOLDINGS INC. AND SUBSIDIARIES <br />Notes to Consolidated Financial Statements <br />December 31, 2010 <br />or any portion of any unvested options to immediately vest and become exercisable upon a sale of the <br />Company or at such other time as the BOD may elect. <br />Stock -based compensation expense is shown as an individual line on the accompanying consolidated <br />statements of operations. The allocation of stock -based expense between "Cost of revenues" and "Selling, <br />general and administrative expenses" for the Successor Period is as follows (in thousands): <br />Cost of revenues $ 221 <br />Selling, general and administrative expenses 595 <br />Total stock -based <br />compensation expense $ 816 <br />The Company accounts for its equity -based awards using ASC Topic 718. This statement requires entities <br />to measure compensation expense for all equity -based awards granted, modified, or settled using the <br />fair -value measurement method and to recognize the costs in income over the requisite service period, <br />which is generally the vesting period. The Company has elected to recognize these costs on a straight -line <br />basis. <br />The fair value of each stock option award is estimated on the date of grant using BSM option - pricing <br />model. The weighted average grant -date value of each option grant awarded during the Successor Period <br />was as follows: <br />Weighted average grant -date value <br />of options granted $ 118.95 <br />Assumptions: <br />Risk -free rate of return 1.73% <br />Expected life in years 6.50 <br />Expected volatility 47.5% <br />Expected dividend yield $ — <br />The risk free rate of return is determined based on a yield curve of U.S. Treasury rates ranging from 5 to <br />7 years which is the period commensurate with the expected life of options granted. Expected life in years <br />is calculated using the simplified method, as permitted under ASC Topic 718, given the Company's lack of <br />historical experience with respect to the lives of options granted and post- vesting termination patterns. <br />Since the Company has no historical basis for determining its own volatility, the expected volatility is <br />established based on a peer group comprising companies similar to that of the Company. The expected <br />dividend yield is zero as the Company has not paid any cash dividends and does not anticipate it will do so <br />in the foreseeable future. <br />31 (Continued) <br />
The URL can be used to link to this page
Your browser does not support the video tag.